Astellas Pharma (Astellas Pharma) EV-to-EBITDA : 18.63 (As of Apr. 30, 2024)

View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Astellas Pharma's enterprise value is $20,971 Mil. Astellas Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $1,126 Mil. Therefore, Astellas Pharma's EV-to-EBITDA for today is 18.63.

The historical rank and industry rank for Astellas Pharma's EV-to-EBITDA or its related term are showing as below:

ALPMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.02 Med: 11.2 Max: 23
Current: 18.62

During the past 13 years, the highest EV-to-EBITDA of Astellas Pharma was 23.00. The lowest was 7.02. And the median was 11.20.

ALPMY's EV-to-EBITDA is ranked worse than
66.67% of 708 companies
in the Drug Manufacturers industry
Industry Median: 14.375 vs ALPMY: 18.62

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-30), Astellas Pharma's stock price is $9.63. Astellas Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.008. Therefore, Astellas Pharma's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Astellas Pharma EV-to-EBITDA Historical Data

The historical data trend for Astellas Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma EV-to-EBITDA Chart

Astellas Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EV-to-EBITDA

Get a 7-Day Free Trial

8.97

8.82

12.81

13.06

12.10

Astellas Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial															11.58	12.10	14.54	23.35	22.04

Competitive Comparison of Astellas Pharma's EV-to-EBITDA

For the Drug Manufacturers - General subindustry, Astellas Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Astellas Pharma's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's EV-to-EBITDA falls into.

Astellas Pharma EV-to-EBITDA Calculation

Astellas Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	20971.303	/	1125.801
	=	18.63

Astellas Pharma's current Enterprise Value is $20,971 Mil.
Astellas Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,126 Mil.

Astellas Pharma (OTCPK:ALPMY) EV-to-EBITDA Explanation

Astellas Pharma's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	9.63	/	-0.008
	=	At Loss

Astellas Pharma's share price for today is $9.63.
Astellas Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.008.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Astellas Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma (Astellas Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

ALPMF:USA 4503:Mexico 4503:Japan YPHA:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.